FAQ on Intensity Therapeutics' $6.6 Million ATM Stock Sales and Its Implications

What is Intensity Therapeutics, Inc.?

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies designed to kill tumors and enhance immune system recognition of cancers using its proprietary technology.

How much did Intensity Therapeutics raise through its ATM stock sales in July 2025?

The company raised $6.6 million in gross proceeds ($6.3 million net) by selling 19,868,658 shares of its common stock at an average price of $0.3323 per share.

What is an At-The-Market (ATM) offering?

An ATM offering is a method where a public company sells its newly issued shares directly into the existing trading market at the prevailing market price, allowing companies to raise capital opportunistically with minimal market disruption and typically lower costs.

What will Intensity Therapeutics use the proceeds from the ATM sales for?

The proceeds will strengthen the company’s balance sheet and allow it to continue advancing its clinical trials into the second half of 2026.

What is INT230-6?

INT230-6 is Intensity’s lead proprietary investigational product candidate, designed for direct intratumoral injection, consisting of two anti-cancer agents and a diffusion enhancer molecule to facilitate drug dispersion throughout tumors, aiming for local disease control and immune system engagement.

How does INT230-6 work?

INT230-6 works by saturating the tumor with potent cytotoxic drugs that diffuse into cancer cells, killing the tumor and releasing neoantigens to engage the immune system, all without causing immunosuppression.

What are the benefits of Intensity Therapeutics’ approach to cancer treatment?

The approach offers a new method to kill tumors and elicit an adaptive immune response quickly, potentially turning deadly cancers into chronic diseases, even for those unresponsive to conventional immunotherapy.

Who is Lewis H. Bender?

Lewis H. Bender is the President and CEO of Intensity Therapeutics, who commented on the strategic advantage of the ATM sales and the company’s plans for the raised capital.

How many shares of common stock does Intensity Therapeutics have outstanding as of July 31, 2025?

Following the ATM sales, the company has 46,035,081 shares of common stock issued and outstanding as of July 31, 2025.

Where can I find more information about Intensity Therapeutics and its products?

More information can be found on Intensity Therapeutics’ official website at https://intensitytherapeutics.com/.